Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
1, 2026, the company said it will no longer cover GLP-1 medications for weight loss for employers with fewer than 100 employees
With Bydureons remarkable profile (nearly two points in A1c reduction, weight loss, much less nausea than Byetta, convenience of a once-weekly shot), we would have thought at least the FDA could have approved the drug in a population that did not include individuals with impaired renal systems, assuming this is the population in question
These findings suggest that GLP treatment is associated with higher resting cardiovascular activation and reduced parasympathetic activity , indicating increased physiological load reported across studies[1]
The friction of managing multiple tools across that journey is real, and it compounds over time
